JMF4073, an inhibitor of thymidine monophosphate (TMP) and cytidine monophosphate (CMP) kinases, exhibits IC50 values of 0.16 μM and 0.17 μM, respectively. This compound effectively eliminates wild-type (WT)-Bcr-Abl-transformed myeloid cells both in vitro and in vivo.

WT-Bcr-Abl cells exhibit high sensitivity to JMF4073 with a GI50 of 0.67 μM, compared to 1.5 μM in T315I-Bcr-Abl-32D cells and 4.2 μM in untransformed 32D cells. The overall tyrosine phosphorylation levels in these cells remain unaffected by JMF4073 treatment.

JMF4073 (5 mg/kg; intraperitoneal injection; daily; for 14 days) was demonstrated to significantly lower the white blood cell count in C3H/HeNCrNarl mice carrying WT-Bcr-Abl-32D chronic myeloid leukemia (CML) cells. Moreover, administration of JMF4073 led to an extension in the survival times of these leukemia-afflicted mice.